NORTHWEST BIOTHERAPEUTICS, INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.464 USD | +0.87% |
|
-1.72% | -33.81% |
| Mar. 21 | Northwest Biotherapeutics, Inc. Appoints Pat Sarma to Its Board of Directors | CI |
| Mar. 14 | Northwest Biotherapeutics, Inc. Announces Retirement of Jerry Jasinowski from the Board of Directors | CI |
Presenter SpeechLinda Powers (Executives)So good afternoon, everybody. Thank you so much for c...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Northwest Biotherapeutics, Inc. is a biotechnology company. The Company is focused on developing personalized immune therapies for cancer. It has developed a platform technology, DCVax, which uses activated dendritic cells to mobilize a patient's own immune system to attack their cancer. The Company's product line includes DCVax-L and DCVax-Direct. DCVax-L is designed to treat solid tumor cancers in which the tumors can be surgically removed. It has completed a 331-patient international Phase III trial of DCVax-L for Glioblastoma multiforme brain cancer (GBM). DCVax-Direct, is designed to treat inoperable solid tumors. A 40-patient Phase I trial has been completed and included treatment of a diverse range of more than a dozen types of cancers. The Companyâs wholly owned subsidiaries include Flaskworks, LLC, Northwest Biotherapeutics Limited, Aracaris Capital, Ltd, Northwest Biotherapeutics B.V., and NW Bio GmbH.
| 1st Jan change | Capi. | |
|---|---|---|
| -33.81% | 554M | |
| -1.01% | 104B | |
| +5.72% | 97.47B | |
| +5.71% | 22.25B | |
| -13.32% | 21.68B | |
| -9.70% | 18.2B | |
| -39.98% | 17.02B | |
| -10.47% | 16.36B | |
| +8.69% | 14.39B | |
| +39.89% | 12.37B |
- Stock Market
- Equities
- NWBO Stock
- News Northwest Biotherapeutics, Inc.
- Transcript : Northwest Biotherapeutics, Inc. - Shareholder/Analyst Call
